Medicare adds penicillin allergy testing to preventive care for seniors

What it does

This bill adds penicillin allergy verification and evaluation to Medicare's covered preventive services for seniors, requiring doctors to identify patients with reported penicillin allergies, assess whether the allergy is real, provide information about the health risks of false allergy labels, and refer patients to allergy specialists when appropriate. The bill is based on evidence that over 90% of patients labeled with penicillin allergies can safely take the drug, and that false labels lead to worse health outcomes and higher costs.

Why we flagged it

The bill expands Medicare's preventive services to include a clinical assessment that corrects a widespread diagnostic error, improving patient outcomes and reducing unnecessary antibiotic resistance. This is straightforward public-health policy, not a market intervention or regulatory carve-out.

What the text implies

• Penicillin allergy 'delabeling' may increase penicillin prescribing, potentially affecting antibiotic resistance patterns and the market share of alternative antibiotics (cephalosporins, fluoroquinolones) among seniors.
• The bill's allowance for separate payment for 'structured penicillin allergy validation and evaluation services' on the same day as preventive visits may create a new billable service category, generating revenue for allergy/immunology specialists and diagnostic labs.
• Widespread delabeling of penicillin allergies could reduce demand for alternative antibiotics, affecting pharmaceutical companies that market non-penicillin options to seniors.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Seniors gain access to a covered preventive service that can correct a widespread misdiagnosis (90%+ of reported penicillin allergies are false), reducing unnecessary hospitalizations, infections, and mortality while lowering overall healthcare costs. The service is voluntary and evidence-based, with no restrictions on citizens' existing rights or remedies.

Who stands to gain

• allergy and immunology specialists
• diagnostic laboratories (allergy testing)
• penicillin and beta-lactam antibiotic manufacturers

Named in the bill

Centers for Disease Control and Prevention (CDC), American Academy of Allergy, Asthma & Immunology, Journal of the American Medical Association (JAMA), Journal of Allergy and Clinical Immunology, New England Journal of Medicine, Annals of Allergy, Asthma & Immunology, Medicare, Social Security Act Section 1861, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA) — and 1 more

Where it stands

9 cosponsors: 5 Democrats, 4 Republicans.

• Oct 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Oct 10, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $286,331 in lobbying spend. A filing names 44 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

H. Griffith, the sponsor, reported $1,286,206 in PAC receipts in the 2026 cycle.

• American Academy of Otolaryngology-head and Neck Surgery — $286,331 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.